Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Lam, John C ^a   Somayaji, Ranjani ^a   Surette, Michael G ^b,c   Rabin, Harvey R ^a,c   Parkins, Michael D ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Biomarker; Bronchiectasis; Cefepime; Failure; Heterogeneity; Outcome; Treatment

Indexed keywords

BETA LACTAM ANTIBIOTIC; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL LOAD; BACTERIUM IDENTIFICATION; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DENSITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG RESPONSE; FOLLOW UP; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SPUTUM ANALYSIS; SPUTUM DENSITY; TREATMENT DURATION; ADULT; COMPLICATION; DISEASE COURSE; EVALUATION STUDY; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; SPUTUM; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME;

EID: 84926672744     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0856-5     Document Type: Article

References (60)

1. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995-2005. Chest. 2009;136(6):1554-60.
2. Kerem E, Corey M, Stein R, Gold R, Levison H. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J. 1990;9(7):494-8.
3. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32(4):277-87.
4. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-8.
5. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42.
6. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10(2):S79-81.
7. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007;62(4):360-7.
8. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64-72.
9. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999;103(6):e72.
10. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627-32.
11. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010;45(2):127-34.
12. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002;166(12 Pt 1):1550-5.
13. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001;286(21):2683-9.
14. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-8.
15. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest. 2012;141(2):485-93.
16. Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest. 2013;144(5):1659-70.
17. Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, et al. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax. 2013;68(10):929-37.
18. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141(4 Pt 1):914-21.
19. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
20. Denton M. Laboratory standards for processing microbiological samples from people with cystic fibrosis. In. Edited by Trust UCF. Bromley: UK CF Trust; Sept, 2010. Available at; https://www.cysticfibrosis.org.uk/media/82034/CD_Laboratory_Standards_Sep_10.pdf last accessed Mar 3, 2015.
21. Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol. 2014;52(4):1127-35.
22. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. In. Edited by (CLSI) CaLSI, vol. M100-S19 Vol. 29 No. 3 2009: 1-156. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA
23. Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007;26(8):834-8.
24. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61-6.
25. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-56.
26. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30.
27. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-40.
28. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988;112(4):547-54.
29. McLaughlin FJ, Matthews Jr WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983;147(3):559-67.
30. Deschaght P, Schelstraete P, Van Simaey L, Vanderkercken M, Raman A, Mahieu L, et al. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One. 2013;8(11):e79010.
31. Parkins MD, Sibley CD, Surette MG, Rabin HR. The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr Pulmonol. 2008;43(5):490-7.
32. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr. 1980;97(1):144-7.
33. Sibley CD, Grinwis ME, Field TR, Parkins MD, Norgaard JC, Gregson DB, et al. McKay agar enables routine quantification of the 'Streptococcus milleri' group in cystic fibrosis patients. J Med Microbiol. 2010;59(Pt 5):534-40.
34. Sibley CD, Parkins MD, Rabin HR, Surette MG. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs. 2009;10(8):787-94.
35. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One. 2013;8(4):e62917.
36. Twomey KB, Alston M, An SQ, O'Connell OJ, McCarthy Y, Swarbreck D, et al. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PLoS One. 2013;8(12):e82432.
37. Fothergill JL, Ledson MJ, Walshaw MJ, McNamara PS, Southern KW, Winstanley C. Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients. J Cyst Fibros. 2013;12(6):675-81.
38. Reid DW, Latham R, Lamont IL, Camara M, Roddam LF. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2013;12(6):688-99.
39. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros. 2011;10(5):357-65.
40. Goeminne PC, Kicinski M, Vermeulen F, Fierens F, De Boeck K, Nemery B, et al. Impact of air pollution on cystic fibrosis pulmonary exacerbations: a case-crossover analysis. Chest. 2013;143(4):946-54.
41. McCuaig S, Martin JG. How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. Lancet Respir Med. 2013;1(2):137-47.
42. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5.
43. Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006;61(11):969-74.
44. Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis. 2012;9(1):9-16.
45. Etherington C, Naseer R, Conway SP, Whitaker P, Denton M, Peckham DG. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J Cyst Fibros. 2014;13(1):49-55.
46. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A. 2008;105(39):15070-5.
47. Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One. 2013;8(4):e60225.
48. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, et al. Pseudomonas aeruginosa Population Diversity and Turnover in Cystic Fibrosis Chronic Infections. Am J Respir Crit Care Med. 2011;183(12):1674-9.
49. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2013;5:CD006682.
50. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7(5):338-48.
51. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176-89.
52. Hamelin BA, Moore N, Knupp CA, Ruel M, Vallee F, LeBel M. Cefepime pharmacokinetics in cystic fibrosis. Pharmacotherapy. 1993;13(5):465-70.
53. Huls CE, Prince RA, Seilheimer DK, Bosso JA. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother. 1993;37(7):1414-6.
54. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:CD001915.
55. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006;173(12):1356-62.
56. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11(4):293-9.
57. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, et al. Pseudomonas aeruginosa in vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. Am J Respir Crit Care Med. 2014;190(3):289-97.
58. Mayer-Hamblett N, Ramsey BW, Kulasekara H, Wolter DJ, Houston L, Pope C, et al. Pseudomonas aeruginosa Phenotypes Associated with Eradication Failure in Children with Cystic Fibrosis. Clin Infect Dis. 2014;59(5):624-31.
59. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158-61.
60. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123(5):1495-502.